Retatrutide

Mechanism

Evidence tier: 1 — Triple agonist receptor pharmacology characterized in TRIUMPH-1 Phase 2 plus mechanistic preclinical work; downstream weight-loss effect directly measured in RCTs.

Retatrutide (LY3437943) is Eli Lilly's investigational triple agonist of the GLP-1, GIP, and glucagon receptors. It is the first molecule in clinical development to combine all three incretin/counter-regulatory receptor activities in a single peptide. GLP-1 receptor agonism (the semaglutide mechanism) drives satiety, slowed gastric emptying, and pancreatic insulin response. GIP receptor agonism (added in tirzepatide) appears to enhance insulin secretion and may contribute to favorable weight-loss and lipid effects. The novel third axis is glucagon receptor agonism, which increases energy expenditure and hepatic lipid mobilization — the same mechanism that drives the metabolic effects of glucagon in normal physiology, but harnessed in a controlled, balanced way alongside the GLP-1/GIP arms that mute the glucagon-driven hyperglycemia that would otherwise result. The net effect is a substantially larger weight-loss signal than has been seen with any prior incretin class, with the glucagon arm providing a metabolic-rate contribution on top of the appetite-suppression mechanism shared with GLP-1 and GLP-1/GIP agents.

Typical protocols

Evidence tier: 1 — TRIUMPH-1 Phase 2 dose-finding data and TRIUMPH Phase 3 escalation schedule are RCT-derived. Off-label use of compounded material follows trial dosing by convention.

Retatrutide is not yet FDA-approved as of May 2026, and there is no commercial product. Dosing in current research and the ongoing Phase 3 TRIUMPH program follows the Phase 2 dose-finding work:

• Doses studied: 1, 4, 8, and 12 mg subcutaneously once weekly in TRIUMPH-1 (Jastreboff 2023 PMID 37366315)
• Phase 3 doses: 8 mg and 12 mg weekly are the primary Phase 3 doses
• Escalation: Gradual dose escalation from 2 mg → 4 mg → 8 mg → 12 mg over 16-20 weeks to manage GI tolerability
• Route: Subcutaneous, once-weekly injection (abdomen, thigh, or upper arm)
• Cycle length: TRIUMPH-1 ran 48 weeks; TRIUMPH Phase 3 trials run 68-76 weeks

Compounded retatrutide is being supplied by some 503A pharmacies on a research-use framing in 2026. This is regulatory grey zone — compounded supply of an investigational, not-yet-approved molecule is legally and ethically distinct from compounding of historically-marketed-then-shortage-status drugs like semaglutide and tirzepatide. We do not endorse compounded retatrutide use; the dose-finding work is incomplete, the long-term safety profile is not characterized, and the Phase 3 program is not yet read out.

Evidence by indication

Evidence tier: 1 — TRIUMPH-1 Phase 2 NEJM publication plus TRIUMPH-4 Phase 3 topline (December 2025).

Obesity (TRIUMPH-1, Phase 2): Jastreboff 2023 (PMID 37366315) in NEJM enrolled 338 adults with BMI ≥30 (or ≥27 with comorbidity) without diabetes. At 48 weeks, mean body-weight reduction was 22.8% on retatrutide 8 mg, 24.2% on 12 mg, vs 2.1% on placebo. This is the largest weight-loss effect observed in any published GLP-1-class RCT to date and substantially exceeds the tirzepatide SURMOUNT-1 result (~22.5% at 72 weeks) and semaglutide STEP-1 result (~14.9% at 68 weeks).

Obesity with knee osteoarthritis (TRIUMPH-4, Phase 3): First successful Phase 3 readout, December 2025. Up to 28.7% mean weight loss at 68 weeks (mean −32.3 kg / −71.2 lbs), with concurrent meaningful reduction in osteoarthritis pain (WOMAC score reduction up to 75.8% vs 40.3% placebo).

Type 2 diabetes (Phase 2): A separate Phase 2 program in T2D showed HbA1c reductions of approximately 2.0+ percentage points at higher doses with concurrent ~15-17% weight loss.

Type 2 diabetes, obstructive sleep apnea, MASLD, chronic low back pain, cardiometabolic outcomes (TRIUMPH Phase 3): Seven additional Phase 3 readouts expected through 2026, including TRIUMPH-3 in patients with established cardiovascular disease.

The evidence base is the strongest of any peptide on this directory that is not yet FDA-approved. The unknowns are durability beyond 76 weeks, long-term safety with sustained glucagon-receptor agonism, and the safety profile in older and cardiometabolically high-risk populations being studied in Phase 3.

Safety profile

Evidence tier: 1 — Phase 2 RCT plus emerging Phase 3 data; long-term (>2 year) human safety data is not yet available.

The Phase 2 adverse-event profile is dominated by GI events (nausea, diarrhea, vomiting, constipation) consistent with the GLP-1/GIP class. Most are mild-to-moderate and concentrated in the dose-escalation phase. Heart rate elevation of approximately 5-7 bpm is observed at the higher doses, attributed to glucagon-receptor activity — this is mechanistically expected and tracked in the Phase 3 cardiovascular-outcomes studies. The December 2025 TRIUMPH-4 readout flagged a separate safety signal that Lilly is characterizing; the specific signal has not been fully detailed in topline communication and is being assessed in the full Phase 3 dataset.

Phase 2 did not show clinically meaningful glycemic deterioration despite glucagon-receptor agonism — the GLP-1/GIP arms appear to offset the hyperglycemic potential of glucagon agonism. Long-term safety with sustained triple-agonist exposure is not yet characterized; concerns parallel the rest of the GLP-1 class (medullary thyroid carcinoma in rodent models, pancreatitis signal, gallbladder events) with the additional glucagon-axis questions still being studied.

Contraindications by analogy with the GLP-1 class: personal or family history of medullary thyroid carcinoma, MEN-2 syndrome, prior severe pancreatitis, severe gastroparesis, pregnancy. The Phase 3 program excludes these populations.

Where it fits relative to alternatives

Evidence tier: 5 — Editorial positioning across the obesity-pharmacotherapy landscape; subject to revision on Phase 3 readouts.

In the obesity pharmacotherapy hierarchy as of May 2026:

• Semaglutide (FDA-approved, Wegovy): GLP-1 monoagonist, ~15% weight loss, established safety
• Tirzepatide (FDA-approved, Zepbound): GLP-1/GIP, ~22% weight loss, established safety; current first-line in non-diabetic obesity
• Retatrutide (Phase 3): GLP-1/GIP/glucagon, ~24-29% weight loss in trials, safety profile maturing — if approved, would be the highest-efficacy weight-loss molecule available
• Orforglipron (Phase 3, oral): oral non-peptide GLP-1, ~14-15% weight loss, the convenience-and-cost play
• CagriSema (Phase 3): semaglutide + cagrilintide, complementary mechanism to retatrutide

Retatrutide's positioning will be highest-efficacy injectable when approved, likely reserved for severe obesity, cardiometabolic risk, or tirzepatide non-response. Cost and access will be the primary barriers initially. See the Retatrutide vs Tirzepatide comparison for the most-asked head-to-head question.

Regulatory status + access

Evidence tier: 5 — Regulatory-process content.

Retatrutide is investigational as of May 2026 — not FDA-approved for any indication. Expected NDA filing in Q4 2026 per Lilly's investor communications, with potential FDA approval in 2027. The TRIUMPH Phase 3 program comprises eight registrational trials covering obesity, T2D, OSA, OA, MASLD, chronic low back pain, and cardiometabolic outcomes. Until FDA approval, lawful access is via clinical trial enrollment only — clinicaltrials.gov lists active TRIUMPH studies. Compounded retatrutide circulating via 503A pharmacies on a research-use framing is regulatorily distinct from compounded semaglutide/tirzepatide (which are based on FDA-approved molecules in shortage status) and we do not endorse this pathway. WADA: retatrutide as a peptide hormone is prohibited for athletes regardless of approval status.

References

• Jastreboff AM, Kaplan LM, Frías JP, et al. 2023. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. PMID 37366315
• Aronne LJ, Horn DB, le Roux CW, et al. 2025. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. PMID 40353578
• Wilding JPH, Batterham RL, Calanna S, et al. 2021. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. PMID 33567185
• Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. 2023. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. PMID 37952131
• Lilly. Triple Agonist Retatrutide Phase 3 TRIUMPH Program — Topline Readouts 2025-2026. investor.lilly.com

Limitations

Retatrutide should not be used outside a clinical trial setting in patients with personal or family history of medullary thyroid carcinoma, MEN-2 syndrome, prior severe pancreatitis, severe gastroparesis, pregnant or nursing patients, or anyone with active malignancy. Patients with cardiovascular disease, type 1 diabetes, severe hepatic impairment, or eGFR <30 should only access via the active Phase 3 TRIUMPH cardiometabolic studies under specialist supervision. Patients subject to WADA testing should not use it.

The cited evidence cannot tell us long-term (>76 week) durability of effect, the full Phase 3 safety dataset (only TRIUMPH-4 has read out so far), how the December 2025 Phase 3 safety signal will be characterized, performance in patients over 75, or whether the glucagon-receptor agonism produces any clinically meaningful effect on lean mass preservation relative to GLP-1 monoagonists. We would change our framing on each TRIUMPH Phase 3 readout through 2026, the eventual FDA action, and any pharmacovigilance data emerging from post-approval use.